CD28 and neoplasm: ➢ Trispecific T cell engager – The trispecific approach involves targeting CD3+ T cells along with two different tumor associated antigens, or targeting CD3 and CD28 on the T cell along with the tumor associated antigen to enhance specificity, lower toxicity, and improve T cell activation (120, 121).